发明授权
US07696218B2 Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
有权
取代的MAPK / ERK激酶的1,3-二烷基-2,4-二氧代-6-（芳基氨基）-1,2,3,4-四氢嘧啶-5-异羟肟酸抑制剂
- 专利标题： Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
- 专利标题（中）： 取代的MAPK / ERK激酶的1,3-二烷基-2,4-二氧代-6-（芳基氨基）-1,2,3,4-四氢嘧啶-5-异羟肟酸抑制剂
-
申请号： US11876635申请日： 2007-10-22
-
公开(公告)号： US07696218B2公开(公告)日： 2010-04-13
- 发明人: Qing Dong , Stephen W. Kaldor
- 申请人： Qing Dong , Stephen W. Kaldor
- 申请人地址： US CA San Diego
- 专利权人： Takeda San Diego, Inc.
- 当前专利权人： Takeda San Diego, Inc.
- 当前专利权人地址： US CA San Diego
- 代理商 David Stemerick; Mitchell R. Brustein
- 主分类号： A61K31/505
- IPC分类号： A61K31/505
摘要：
Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.
公开/授权文献
- US20080125437A1 MAPK/ERK KINASE INHIBITORS 公开/授权日：2008-05-29
信息查询
